Wolverine Stack Dosage Protocol
BPC-157 + TB-500 loading and maintenance phases, week by week, with injection-site notes and the evidence framing this stack actually deserves.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
Evidence framing
The Wolverine Stack is a community protocol, not a clinically validated combination. There are no published human RCTs of BPC-157 + TB-500 co-administration. Each individual peptide has limited human trial data on its own; the combination is even less studied. Use the protocol below as reference for what is commonly done, not as a recommendation.
The Wolverine Stack pairs BPC-157 (250–500 mcg/day subQ) with TB-500 (2–2.5 mg subQ twice weekly) for soft-tissue and tendon recovery. The name and the protocol both originate in athletic-recovery and biohacker communities, not clinical trials. The combination is widely used in 503A/503B compounding peptide therapy, but the pairing has never been formally tested in a human RCT. The protocol below reflects the most commonly cited loading-plus-maintenance schedule across practitioner sources in 2026 — it is descriptive, not prescriptive.
What's in the Wolverine Stack
Wolverine Stack Protocol Phases
Total cycle: 8 weeks of active dosing, followed by a 4-week off-cycle (12 weeks total). Each phase below shows the dose and frequency for every component during that window.
Loading Phase
Weeks 1–4| Component | Dose | Frequency |
|---|---|---|
| BPC-157 | 250–500 mcg | Daily, subQ (often split AM + PM) |
| TB-500 | 2–2.5 mg | 2× per week, subQ (Monday + Thursday pattern) |
Maintenance Phase
Weeks 5–8| Component | Dose | Frequency |
|---|---|---|
| BPC-157 | 250 mcg | Once daily, subQ |
| TB-500 | 2 mg | Once per week, subQ |
Off-Cycle
Weeks 9–12| Component | Dose | Frequency |
|---|---|---|
| BPC-157 | — | Hold |
| TB-500 | — | Hold |
Injection Site Notes
BPC-157 is commonly injected subcutaneously near the injury site (e.g., around the Achilles, lateral epicondyle, rotator cuff insertion) for localized tendon and ligament work — community theory holds that local administration improves vascular and tendon repair, though there is no human pharmacokinetic data confirming this is necessary. TB-500 is almost always injected systemically (abdomen or thigh subQ); the molecule is larger, has a longer functional duration, and distributes systemically, so localized injection is not considered necessary. Critically: do not co-mix BPC-157 and TB-500 in the same syringe. Sterility and stability concerns arise with co-mixing, and your compounding pharmacy will typically supply them as separate vials.
Why People Stack These
BPC-157 is described in community practice as faster-acting on inflammation, gut, and vascular tissue. TB-500 is described as slower-acting on cell migration, actin regulation, and broader tissue regeneration. The pairing is positioned as covering both fast and slow phases of soft-tissue repair simultaneously. The mechanistic story is plausible but mechanistic plausibility is not the same as validated efficacy — the combination has not been formally tested in humans.
The Wolverine Stack inherits the safety profile of both components, including a relative contraindication in active malignancy due to the angiogenic and pro-migratory activity of TB-500.
- •BPC-157 individual safety: animal data is robust, human RCT data is minimal. Most practitioners report it as well-tolerated.
- •TB-500 individual safety: angiogenic and pro-migratory activity raises specific concerns in active or recent malignancy. WADA-banned for athletes.
- •Combined safety: no published human studies of the combination. Theoretical risks compound — if one peptide is contraindicated for you, the stack is contraindicated.
- •Do not run continuously. Cycle 8 weeks on, 4 weeks off.
- •Stop and consult your provider if systemic side effects develop (BP changes, GI symptoms, fatigue beyond expected recovery context).
Wolverine Stack FAQ
Anecdotal reports describe gut and inflammation improvements within 1–2 weeks, with tendon and ligament responses reported over 3–6 weeks. The 8-week cycle is designed around the slower tendon-remodeling timeline. Tendon biology is genuinely slow; pro-healing peptides do not change that fundamental timeline by orders of magnitude.
Some practitioners run a 4-week loading-only protocol for milder injuries. The full 8-week loading-plus-maintenance pattern is designed for moderate-to-severe soft-tissue injuries where remodeling will continue past the loading phase.
Yes. Tendon and ligament remodeling responds to controlled mechanical stress. Combining the stack with eccentric loading, isometric holds, and progressive return-to-sport work produces better outcomes than either alone in clinical practice. Most experienced practitioners credit the mechanical input — not the peptides alone — for durable recovery.
Most protocols specify a 4-week off-cycle before any repeat. This break allows for assessment of recovery outcomes and reduces theoretical risks of continuous angiogenic stimulation. Back-to-back cycles without a break are not the standard.
Both BPC-157 and TB-500 are available through 503A/503B compounding pharmacies in the United States with a provider prescription. Direct-to-consumer 'research peptide' sales are not a legal channel for human use. Athletes under WADA-aligned testing should be aware that TB-500 is banned.
Sources
Related Charts
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.